Construction and Screening of A Novel Adeno-Associated Virus Vector Targeting Myocardial Tissue
-
摘要: 为了构建以心肌为靶点的基因治疗载体，通过DNA shuffling技术对选择的8种AAV（AAV1~AAV4，AAV6~AAV9）衣壳基因进行了重组，构建了随机突变体AAV衣壳文库。将随机突变体AAV衣壳文库在小鼠体内直接筛选，最终筛选得到高心肌靶向和低肝脏靶向的新型AAV衣壳：AAVH50与AAVH59。通过尾静脉注射，将AAV携带的荧光素酶（Luc）基因递送到小鼠体内，结果表明：在检测的11个组织中，AAVH50与AAVH59在心肌组织的基因表达高于其他组织。与AAV6、AAV9相比，AAVH50与AAVH59心肌中的Luc表达水平相近，肝脏中的表达明显低于AAV9。AAVH50和AAVH59感染原代新生大鼠心肌细胞后，AAVH59在心肌直接感染的效率明显高于AAV9。
-
关键词:
- DNA shuffling /
- 腺相关病毒 /
- 体内筛选 /
- 心肌 /
- 靶向
Abstract: Cardiomyopathy is a common disease and is regarded as an important cause of premature death. The development of a gene therapy vector for cardiomyopathy is the key to gene therapy of cardiomyopathy. In order to build a gene therapy vector targeting myocardium, the eight selected AAV (AAV1−AAV4, AAV6−AAV9) capsid genes were recombined by DNA shuffling technology, and a random mutant AAV capsid library was constructed in mice direct screening. Finally the new AAV capsids with high myocardial targeting and low liver targeting, AAVH50 and AAVH59, were screened. Through the tail vein injection, the luciferase (Luc) gene carried was delivered to mice. It was found that among the eleven tissues tested, the gene expressions of AAVH50 and AAVH59 in myocardial tissue were higher than other tissues. Compared with AAV6 and AAV9, AAVH50 and AAVH59 expressed similar levels of luciferase in the myocardium, and the expression in the liver significantly decreased AAV9. After AAVH50 and AAVH59 infected primary neonatal rat cardiomyocytes, the efficiency of the selected AAVH59 in direct myocardial infection was significantly higher than that of AAV9. Therefore, this study screened to obtain a new type of AAV vector with high targeting to myocardium, and to the liver and low targeting, which is expected to provide a new type of AAV vector for gene therapy of myocardial diseases.-
Key words:
- DNA shuffling /
- adeno-associated virus /
- in vivo screening /
- cardiac muscle /
- targeting
-
图 1 DNA shuffling技术构建突变体AAV衣壳文库与小鼠体内筛选
Figure 1. Construction of mutant AAV capsid library by DNA shuffling technology and in vivo screening in mice
图 3 注射AAV9-CMV-Luc、AAVH50-CMV-Luc、AAVH59-CMV-Luc后小鼠荧光素酶活体成像。
Figure 3. In vivo imaging of mouse luciferase after injection of AAV9-CMV-Luc、AAVH50-CMV-Luc、AAVH59-CMV-Luc
图 4 尾静脉注射AAV载体后各种小鼠组织中的荧光素酶活性
Figure 4. Luciferase activity in various mouse tissues after tail vein injection of AAV vector
图 5 尾静脉注射AAV载体后各种小鼠组织中载体基因组拷贝数
Figure 5. Vector genome copy numbers in various mouse tissues after tail vein injection of AAV vector
-
[1] MARON M S, OLIVOTTO I, ZENOVICH A G, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction[J]. Circulation, 2006, 114(21): 2232-2239. doi: 10.1161/CIRCULATIONAHA.106.644682 [2] LUK A, AHN E, SOOR G S, et al. Dilated cardiomyopathy: A review[J]. Journal of Clinical Pathology, 2009, 62(3): 219-225. doi: 10.1136/jcp.2008.060731 [3] NIHOYANNOPOULOS P, DAWSON D. Restrictive cardiomyopathies[J]. European Journal of Echocardiography, 2009, 10(8): 23-33. [4] ARGULIAN E, SHERRID M V, MESSERLI F H. Misconceptions and facts about hypertrophic cardiomyopathy[J]. The American Journal of Medicine, 2016, 129(2): 148-152. doi: 10.1016/j.amjmed.2015.07.035 [5] XIAO X, LI J, SAMULSKI R J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector[J]. Journal of Virology, 1996, 70(11): 8098-8108. doi: 10.1128/JVI.70.11.8098-8108.1996 [6] NASO M F, TOMKOWICZ B, PERRY W L, et al. Adeno-associated virus (AAV) as a vector for gene therapy[J]. Biodrugs, 2017, 31(4): 317-334. doi: 10.1007/s40259-017-0234-5 [7] GREGOREVIC P, ALLEN J M, MINAMI E, et al. RAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice[J]. Nature Medicine, 2006, 12(7): 787-789. doi: 10.1038/nm1439 [8] PACAK C A, MAH C S, THATTALIYATH B D, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transductionin vivo[J]. Circulation Research, 2006, 99(4): E3-E9. [9] SU H, HUANG Y, TAKAGAWA J, et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect[J]. Gene Therapy, 2006, 13(21): 1495-1502. doi: 10.1038/sj.gt.3302787 [10] PALOMEQUE J, CHEMALY E R, COLOSI P, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo[J]. Gene Therapy, 2007, 14(13): 989-997. doi: 10.1038/sj.gt.3302895 [11] GREGOREVIC P, BLANKINSHIP M J, ALLEN J M, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors[J]. Nature Medicine, 2004, 10(8): 828-834. doi: 10.1038/nm1085 [12] RENGO G, LYMPEROPOULOS A, ZINCARELLI C, et al. Myocardial adeno-associated virus serotype 6-betaarkct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure[J]. Circulation, 2009, 119(1): 89-98. doi: 10.1161/CIRCULATIONAHA.108.803999 [13] BISH L T, MORINE K, SLEEPER M M, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat[J]. Human Gene Therapy, 2008, 19(12): 1359-1368. doi: 10.1089/hum.2008.123 [14] INAGAKI K, FUESS S, STORM T A, et al. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8[J]. Molecular Therapy, 2006, 14(1): 45-53. doi: 10.1016/j.ymthe.2006.03.014 [15] WANG L, CAO O, SWALM B, et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer[J]. Gene Therapy, 2005, 12(19): 1453-1464. doi: 10.1038/sj.gt.3302539 [16] COLELLA P, SELLIER P, COSTA VERDERA H, et al. AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate pompe mice[J]. Molecular Therapy Methods & Clinical Development, 2019, 12: 85-101. [17] CALCEDO R, MORIZONO H, WANG L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents[J]. Clinical and Vaccine Immunology, 2011, 18(9): 1586-1588. doi: 10.1128/CVI.05107-11 [18] BARTEL M A, WEINSTEIN J R, SCHAFFER D V. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery[J]. Gene Therapy, 2012, 19(6): 694-700. doi: 10.1038/gt.2012.20 [19] SONNTAG F, SCHMIDT K, KLEINSCHMIDT J A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(22): 10220-10225. doi: 10.1073/pnas.1001673107 [20] NAM H J, LANE M D, PADRON E, et al. Structure of adeno-associated virus serotype 8: A gene therapy vector[J]. Journal of Virology, 2007, 81(22): 12260-12271. doi: 10.1128/JVI.01304-07 [21] MIYAKE K, MIYAKE N, YAMAZAKI Y, et al. Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification[J]. Journal of Nippon Medical School, 2012, 79(6): 394-402. doi: 10.1272/jnms.79.394 [22] GOVINDASAMY L, PADRON E, MCKENNA R, et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4[J]. Journal of Virology, 2006, 80(23): 11556-11570. doi: 10.1128/JVI.01536-06 [23] GRIMM D, LEE J S, WANG L, et al. In vitro andin vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses[J]. Journal of Virology, 2008, 82(12): 5887-5911. doi: 10.1128/JVI.00254-08 [24] WANG M, CROSBY A, HASTIE E, et al. Prediction of adeno-associated virus neutralizing antibody activity for clinical application[J]. Gene Therapy, 2015, 22(12): 984-992. doi: 10.1038/gt.2015.69 [25] KIENLE E, SENIS E, BORNER K, et al. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling[J]. Journal of Visualized Experiments, 2012(62): 3819. [26] MULLER O J, KAUL F, WEITZMAN M D, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors[J]. Nature Biotechnology, 2003, 21(9): 1040-1046. doi: 10.1038/nbt856 [27] ZIEGLER T, ISHIKAWA K, HINKEL R, et al. Translational aspects of adeno-associated virus-mediated cardiac gene therapy[J]. Human Gene Therapy, 2018, 29(12): 1341-1351. doi: 10.1089/hum.2017.229 [28] MAHESHRI N, KOERBER J T, KASPAR B K, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors[J]. Nature Biotechnology, 2006, 24(2): 198-204. doi: 10.1038/nbt1182 [29] YANG L, JIANG J, DROUIN L M, et al. A Myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(10): 3946-3951. doi: 10.1073/pnas.0813207106 -
下载:
点击查看大图
图(6)
计量
- 文章访问数: 1740
- HTML全文浏览量: 968
- PDF下载量: 45
- 被引次数: 0
